Surrogate Endpoints for Clinical Trials: Panacea or Pandora Box?

Date: 
February 19, 2021
Time: 
12:10pm - 1:00pm
Place: 
Zoom - Registry Link Below

Surrogate endpoints, or endpoints that take the place of primary disease endpoints, can be measured quickly and cheaply, and allow randomized trials to reduce sample size, study duration and ultimately the cost of drug/device development for regulatory approval. Sound too good to be true? Dr. McCulloch will discuss some of the methodologic controversies, dating back over 30 years, regarding what it takes to prove adequate surrogacy. Dr. Black will discuss a project in which a group he is leading is attempting to gain formal FDA approval for bone density change as a surrogate for fracture risk for trials of osteoporosis therapies.

 

 

     Image result for Charles McCulloch photo ucsfImage result for dennis black photo ucsf

 

Speakers: Charles McCulloch, PhD | Dennis Black, PhD | Professors, Epidemiology & Biostatistics, UCSF

 

Register: http://eepurl.com/g1X35P 

Event Type: 
DEB Seminar